Lyumjev (insulin lispro-aabc injection) / Eli Lilly - LARVOL DELTA

Ultrarapid Lispro (Lyumjev) Has an Improved Pharmacokinetic Profile for Exercise Compared With Humalog, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion. (PubMed, Diabetes Care) - "Using Lyumjev in conventional CSII pump therapy provides more effective BRRs prior to exercise compared with Humalog, with fewer hypoglycemic events in active adults with type 1 diabetes."

Journal • PK/PD data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus

Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (clinicaltrials.gov) - P=N/A | N=11 | Completed | Sponsor: Mark D. DeBoer, MD, MSc., MCR | Recruiting ➔ Completed | N=20 ➔ 11

Enrollment change • Trial completion • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

GLUCAGON-ENHANCED INSULIN ABSORPTION IMPROVES GLYCAEMIC CONTROL IN PIGS (ATTD 2026) - "This study investigated whether the vasodilating effect of nanogram doses of glucagon accelerates insulin absorption enough to improve postprandial glucose control. Pure Lyumjev (insulin) was compared with Lyumjev premixed with 50 ng of glucagon per unit of insulin... Premixing insulin with glucagon reduced postprandial glucose drop in pigs, suggesting that glucagon enhances insulin absorption. These preliminary results support further evaluation of this strategy in larger and longer studies to improve postprandial glucose control without the need for meal announcements."

Insulins for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparison chart: Some available insulins for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500 (clinicaltrials.gov) - P1 | N=25 | Recruiting | Sponsor: Portal Diabetes, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500 (clinicaltrials.gov) - P1 | N=25 | Not yet recruiting | Sponsor: Portal Diabetes, Inc.

New P1 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

SPEED: Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Stanford University | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India (clinicaltrials.gov) - P4 | N=150 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed | N=112 ➔ 150

Enrollment change • Trial completion • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

SPEED: Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Stanford University

New P1 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: Mark D. DeBoer, MD, MSc., MCR | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Nano-Amounts of Glucagon Premixed With Fast-Acting Insulin Lispro: Effect on Insulin Absorption in Pigs. (PubMed, Curr Ther Res Clin Exp) - "Nine pigs were included in the control groups; they received a subcutaneous injection of 10 U of insulin lispro (LyumjevⓇ or HumalogⓇ). A similar trend was observed when HumalogⓇ/glucagon was injected (306 mU×min/L vs 65 mU×min/L, SE = 125), although this difference did not reach statistical significance (P = 0.102) compared with the control groups. This series of proof-of-concept experiments in anesthetized pigs indicate that premixing nanogram doses of glucagon in fast-acting insulin lispro formulations may speed up the absorption of subcutaneously injected insulin."

Journal • Anesthesia

Efficacy of Ultra-rapid and Rapid-Acting Insulin Analogs in Hybrid and Advanced Automated Insulin Delivery Systems among People with Type 1 Diabetes—A Systematic Review and Meta-analysis of Randomized Controlled Trials (ADA 2025) - "Inclusion criteria were RCTs; T1D populations of any age; comparing URIAs (Fiasp® or Lyumjev®) with any type of RIAs; using any type of AID systems. URIAs safely improved glycemia and were comparable to RIAs among T1D people using AID systems. Despite outcomes demonstrating statistical significance, the clinical impact may be small, given the TIR improvement of 1.4% (registration ID: CRD42024578754)."

Metastases • Retrospective data • Review • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India (clinicaltrials.gov) - P4 | N=112 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

MicroGlucag2: Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes (clinicaltrials.gov) - P1/2 | N=30 | Suspended | Sponsor: St. Olavs Hospital | Not yet recruiting ➔ Suspended | Trial primary completion date: Jul 2025 ➔ Nov 2025

Trial primary completion date • Trial suspension • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (clinicaltrials.gov) - P=N/A | N=20 | Not yet recruiting | Sponsor: Mark D. DeBoer, MD, MSc., MCR

New trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

MICRO-AMOUNTS OF GLUCAGON PREMIXED IN FAST-ACTING INSULIN (LYUMJEV®); EFFECT ON INSULIN ABSORPTION AND GLUCOSE CONSUMPTION (ATTD 2025) - "We expect to observe that premixing ng amounts of glucagon added to a fast-acting insulin speed up insulin absorption also in patients with T1D and enhances the effect on glucose metabolism. That will be a major achievement that potentially will benefit all patients with T1D. And it may make a fully automated artificial pancreas possible."

Anesthesia

FIRST CLINICAL REPORT OF THE LILLY TEMPO PERSONALIZED DIABETES MANAGEMENT PLATFORM BOLUS CALCULATOR USE IN FREE LIVING ENVIRONMENT (ATTD 2025) - "The Lilly Tempo Smart Button enables Basaglar®, Humalog®, and Lyumjev® insulin dose-related data to automatically transfer to a compatible App. Use of the IC was consistent across all meals and corrections.Conclusions The aggregate glucose data indicates increased usage of the IC over the 6-week period corresponds to greater trust in the IC recommendations, as a significant percentage of administered doses were within 10% of the IC's suggested dose. Aggregate data indicates meaningful improvement in glycemic outcomes with the Tempo Platform IC over this period."

Clinical • Diabetes • Metabolic Disorders

MicroGlucag2: Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: St. Olavs Hospital

New P1/2 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Investigation of Severe Hypoglycemia Risk Among Patients with Diabetes Treated with Ultra-Rapid Lispro in Japan. (PubMed, Adv Ther) - "This study did not show a statistically significant increase in the incidence and risk of the first severe hypoglycemia event requiring a hospital visit in real-world URLi-treated patients in Japan, compared with a PS-matched cohort of other RAIA-treated patients."

Journal • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Impact of Ultra-Rapid Insulin on Boost and Ease-Off in the Cambridge Hybrid Closed-Loop System for Individuals With Type 1 Diabetes. (PubMed, J Diabetes Sci Technol) - "There were no safety issues when using Boost and Ease-off with ultra-rapid insulins. The use of Fiasp and Lyumjev during Boost or Ease-off resulted in comparable safety and efficacy to using insulin aspart and lispro."

Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

TLV-0332-24: Mealtime or Post-meal Dosing of URLi in Medtronic 780G Hybrid Closed Loop System (clinicaltrials.gov) - P4 | N=50 | Not yet recruiting | Sponsor: Tel-Aviv Sourasky Medical Center

New P4 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India (clinicaltrials.gov) - P4 | N=112 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Jul 2025 ➔ Oct 2025 | Trial primary completion date: Jul 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Glycemic Outcomes with Rapid Insulin vs. Ultrarapid Insulin in Omnipod 5 (OP5) (ADA 2024) - "Ultrarapid insulins (Lyumjev, Fiasp) are designed to reduce post-prandial excursions and may be beneficial in automated pumps. However, satisfaction and bolus overrides improved with ultrarapid insulin. A larger sample size and meal-specific measures are needed to connect patient experience with glycemic outcomes."

Diabetes • Metabolic Disorders

A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India (clinicaltrials.gov) - P4 | N=112 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus